- cafead   Sep 16, 2024 at 11:12: AM
via One of Ipsen’s flagship oncology assets Cabometyx (cabozantinib) will not be gaining an indication in prostate cancer outside the US or Japan after a Phase III trial failed to meet one of its primary endpoints.
article source
article source